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Seven distinct sequence variants of the Epstein-Barr virus latent membrane protein 1 (LMP1) have been
identified by distinguishing amino acid changes in the carboxy-terminal domain. In this study the transmem-
brane domains are shown to segregate identically with the distinct carboxy-terminal amino acid sequences.
Since strains of LMP1 have been shown to differ in abundance between blood and throat washes, nasopha-
ryngeal carcinomas (NPCs) from areas of endemicity and nonendemicity with matching blood were analyzed
by using a heteroduplex tracking assay to distinguish LMP1 variants. Striking differences were found between
the compartments with the Ch1 strain prevalent in the NPCs from areas of endemicity and nonendemicity and
the B958 strain prevalent in the blood of the endemic samples, whereas multiple strains of LMP1 were
prevalent in the blood of the nonendemic samples. The possible selection against the B958 strain appearing in
the tumor was highly significant (P < 0.0001). Sequence analysis of the full-length LMP1 variants revealed
changes in many of the known and computer-predicted HLA-restricted epitopes with changes in key positions
in multiple, potential epitopes for the specific HLA of the patients. These amino acid substitutions at key
positions in the LMP1 epitopes may result in a reduced cytotoxic-T-lymphocyte response. These data indicate
that strains with specific variants of LMP1 are more likely to be found in NPC. The predominance of specific
LMP1 variants in NPC could reflect differences in the biologic or molecular properties of the distinct forms of
LMP1 or possible immune selection.
The Epstein-Barr virus (EBV) is a prevalent human gam-
maherpesvirus that establishes a persistent latent infection in
over 90% of the world’s population (76). EBV can avoid rec-
ognition by the immune system in part through minimal viral
gene expression in resting memory B lymphocytes, alteration
and modification of antigen expression machinery, and alter-
ation of the immune response to infected cells through the
release of anti-inflammatory cytokines (33, 79, 89).
Primary infection is usually asymptomatic, but may result in
infectious mononucleosis, a benign lymphoproliferative dis-
ease whose pathogenesis partially results from the immune
response to EBV infection of B lymphocytes (67). After the
development of the major histocompatibility complex class I
(MHC-I)-restricted T-cell response to EBV antigens, the num-
ber of EBV-infected B cells declines sharply and is eventually
controlled by a functional immune system (11, 46, 66). Al-
though the majority of infections are asymptomatic, EBV in-
fection is also strongly associated with the pathogenesis of
several malignancies including Burkitt’s lymphoma, nasopha-
ryngeal carcinoma (NPC), Hodgkin’s disease (HD), and
AIDS-associated and posttransplant lymphomas (74). NPC is
particularly significant in that it is one of the leading causes of
cancer death in the southern region of China (36).
Virus-specific T lymphocytes are critical for controlling la-
tent EBV infection in healthy individuals, and both CD8 and
CD4 cells have been shown to respond to latently expressed
EBV proteins (54, 63, 64, 77). The strongest cytotoxic T lym-
phocyte, CTL, response is directed against the EBV nuclear
antigens (EBNAs) 3A, -B, and -C to 6, and a minor response
to the latent membrane proteins, LMP2 and LMP1, has been
detected (42, 77). The EBNAs and LMP1 are not expressed in
the persistently infected memory B cells, and only EBNA1 and
LMP2 are thought to be expressed (89).
Under conditions of immunosuppression, EBV expression
may activate to a transforming infection with expansion of the
EBV-infected cells and uncontrolled B-cell proliferation, re-
sulting in the development of posttransplant lymphomas and
AIDS-associated lymphomas (2, 13, 82). In posttransplant lym-
phomas, all of the latent EBV proteins are expressed, including
EBNA1 and -2, the immunodominant EBNA3A to -C, LMP2,
and LMP1 (28, 93). Restoration of the immune response by
reduction of immune suppressive drugs or transfusion of EBV-
specific cytotoxic T lymphocytes (CTL) has been shown to be
effective therapy (34, 78, 86).
In NPC and HD, only the less-immunogenic proteins
EBNA1, LMP1, and LMP2 are expressed (7, 10, 32, 72, 73).
Patients have elevated titers of antibodies to multiple EBV
proteins, and T cells infiltrate the tumor without apparent
cytotoxicity (29, 30, 50, 59, 68, 88). It is possible that this
immune evasion may be due to changes in CTL-recognized
viral epitopes, since MHC-I and transporter-associated pro-
teins (TAP-1 and -2) are still expressed within tumors and may
be upregulated by LMP1 (44, 51, 65).
Several HLA-restricted epitopes have been identified in
EBNA1, LMP1, and LMP2 of the prototype B958 virus (4, 43,
47, 53, 58, 65, 70). Variants of EBV have also been identified
by polymorphisms in the viral genome, including the EBNA3
and LMP1 genes that have led to changes in the known HLA-
restricted epitopes (14, 40). LMP1 variants have been shown to
differ between the blood and tumor tissue in NPC and HD (18,
31, 57, 87). Variants in the EBNA1 and LMP2 genes have also
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been described; however, the same EBNA1 variant was de-
tected in both the tumor and the blood, whereas possible
differences in LMP2 between tumor and the blood have not
been investigated (9, 50, 92).
Work from our laboratory has identified seven distinct
LMP1 variants based on signature changes in the carboxy ter-
minus, and our recent studies indicate that the EBV strains
with distinct forms of LMP1 differ in abundance in blood and
throat washings (18, 84). To determine whether the LMP1
variants were also distinguishable in the transmembrane do-
main of LMP1, the full-length sequences of the seven strains of
LMP1 were determined. Strain-distinguishing changes were
identified in the transmembrane domains, and phylogenetic
analysis revealed that the transmembrane sequences segre-
gated identically to the strains distinguished by the carboxy-
terminal sequence of LMP1 (18).
To determine whether strain differences exist between tu-
mor tissue and blood based on LMP1, samples of NPC and
matching blood were analyzed from both the southern region
where NPC is endemic and the northern region of China where
NPC is not endemic by using a heteroduplex tracking assay
(HTA) that can distinguish all of the LMP1 variants. Many of
the LMP1 variants were detected in the region where NPC is
not endemic, whereas fewer variants were detected in the re-
gion where NPC is endemic. In addition, clear differences were
detected between the tumor and the peripheral blood lympho-
cytes (PBL). The LMP1 variant most frequently detected in
tumor tissue had changes in many of the known and computer-
predicted HLA-restricted epitopes and these changes were
predicted to result in a reduced CTL response. The known
HLA-restricted LMP2 epitopes were also analyzed and, al-
though changes were identified, in most cases these changes
were present in the strains prevalent in tumors and those
prevalent in the blood. These data indicate that strains with
specific variants of LMP1 are more likely to be found in NPC.
The predominance of specific LMP1 variants in NPC could
reflect differences in the biologic or molecular properties of the
distinct forms of LMP1 or possible decreased immune recog-
nition of the LMP1 prevalent in NPC.
MATERIALS AND METHODS
Patient tissue specimens. The NPC tissue biopsies and matching PBL from
regions where NPC is endemic were obtained from the Guangxi Regional Hos-
pital in Nanning, Guangxi Autonomous Region (specimens GX1 to -6 and 138 to
141). The specimens from regions where NPC is not endemic were obtained from
the Cancer Hospital in Beijing (specimens 108, 509, and 614) and the Bai Qui En
Medical University Hospital in Changchun, Jilin Province (specimens 15 to 19
and 22) (87). NPCs C15, C17, 4, 36, 38, 39, 13, 23, 27, 24, 60, as well as pOT,
PTL1, and HLP 11, have been previously described (18). Mono samples 43, 72,
80, 81, 82, 84, 85, 86, and 87 were cell lines derived from throat wash and/or PBL
of European infectious mononucleosis patients. Sample N2 TW (throat wash)
was from a healthy American.
The tumor biopsies from areas of endemicity and nonendemicity were pro-
cessed as previously described (87). Briefly, tissues were Dounce homogenized
on ice in a buffer containing 15 mM NaCl, 15 mM Tris-HCl (pH 8), and 1 mM
EDTA; subjected to four freeze-thaw cycles; and digested with proteinase K-
sodium dodecyl sulfate for 4 h at 56°C. The samples were subjected to phenol-
chloroform extraction, and the DNA was ethanol precipitated. PBL were puri-
fied over lymphocyte separation medium (Organon Teknika) and processed the
same as the biopsies obtained from areas of endemicity and nonendemicity
described above. The remaining frozen tumors were processed as previously
described (75). Tumor specimens were pulverized in a microdismembrator and
suspended in 4 M guanidine isothiocyanate. After centrifugation through a
cesium chloride step gradient, the DNA was dialyzed, proteinase K digested,
phenol-chloroform extracted, and ethanol precipitated. The throat wash sample
was purified as previously described (83).
DNA sequencing. The DNA sequence corresponding to LMP1 was determined
by amplifying 0.3 g of DNA with the PCR by using Taq polymerase (Promega,
Madison, Wis.). The transmembrane domain of LMP1 was amplified by using
primers 168658R (EBV coordinates 168658 to 168677; 5-CTCGTTGGAGTT
AGAGTCAG-3) and 169251L (EBV coordinates 169251 to 169233; 5-ACCT
TCTCTGTCCACTTGGA-3). The PCR product was sequenced with primer
168658R.
Full-length LMP1 was amplified by using the primers LMP3UT (EBV coor-
dinates 168017 to 168036; 5-ATCACGAGGAATTCAATGTGGCTTTTCAG
CCTAG-3) and LMPEco (EBV coordinates169627 to 169607; 5-ATCACGA
GGAATTCCCCGTACTGCCTCCGGCAGAC-3). A second round of PCR
with 6 l of template from the full-length reaction was performed with the
primers FUE (EBV coordinates 168163 to 168183; 5-GTCATAGTAGCTTAG
CTGAAC-3) and 168808L (EBV coordinates 168830 to 168808; 5-GTGGAC
TCTATTGGTTGATCTC-3) for the 3 end of LMP1 and the primers LMPExc
(EBV coordinates 168813 to 168833; 5-CAACCAATAGAGTCCACCAGT-3)
and 169584Ld [EBV coordinates 169584 to 169565; 5-CATCC(A/C)AGAAA
CACGCGTT-3] for the 5 end of LMP1. Primers 168808L and 169584Ld were
used for sequencing. LMP1 sequence of several samples has been previously
described and was reconfirmed (3, 18, 61, 87).
LMP2 was amplified from tumor samples by using the primers 166538R
(5-GTTTTGCAGTCGCTGCYGCA-3) and 167039L (5-GACCTGTTGTCC
CTGAGATG-3) for exon 1, primers 24R (5-GGTCGGATTTCGCCCTTA
TT-3) and 691L (5-CACAGTTACAGCTCCAAGGA-3) for exons 2 and 3,
primers 362R (5-TTTGCAATTTGCCTAACATG-3) and 1015L (5-GATGC
CAAGTTAGAGCTGCGA-3) for exons 4 and 5, and primers 995R (5-TCGC
AGCTCTAACTTGGCATC-3) and 1677L (5-TACAGTGTTGCGATATGG-
3) for exons 6 to 8. LMP2 was amplified from PBL by using primers 362R and
1677L, followed by nested reactions with primers 362R and 1015L and primers
995R and 1677L.
The samples were sequenced at the University of North Carolina-Chapel Hill
Automated DNA Sequencing Facility on a model 3100 genetic analyzer (Applied
Biosystems Division, Perkin-Elmer Cetus, Norwalk, Conn.) by using the ABI
Prism dye terminator cycle sequencing ready reaction kit with AmpliTaq DNA
polymerase FS (Applied Biosystems Division, Perkin-Elmer Cetus).
Phylogenetic analysis. To determine the phylogenetic relationship within the
various EBV amino acid sequences of the transmembrane domain of LMP1 and
the carboxy-terminal amino acid sequence of LMP1, the amino acid sequences
were aligned by using the CLUSTAL W multiple alignment, distance matrices
were calculated by using the two-parameter model (45), and phylogenetic trees
were inferred from the calculated distances by using neighbor joining (80) with
the Vector NTI software program (Invitrogen). Consensus sequences of each
strain were determined with the Vector NTI program by the alignment of the
samples which grouped on the phylogenetic trees.
HTA. Amplification of LMP1 and HTA analysis were performed as previously
described (85). Briefly, LMP1 was amplified from the samples by nested PCR
with 300 ng of DNA template in duplicate independent reactions with Taq
polymerase (Promega, Madison, Wis.). The first round of amplification with
primers LMP3UT and FUC-Hind3 (EBV coordinates 168427 to 168408; 5-AT
CAGAGAGCTTTGACAATGGCCCACATGACC-3) yielded a 411- or a
381-bp product, depending on the presence or absence of the 30-bp deletion.
Nested PCR with 6 l of template from the initial reaction was performed with
the primers FUE-Eco (EBV coordinates 168163 to 168183; 5-ATCACGAGG
AATTCGTCATAGTAGCTTAGCTGAAC-3) and FUC-Hind3, which yielded
a 264- or a 234-bp product.
The phylogenetically distinct LMP1 variants that have been identified include
the prototypic undeleted B958 and other undeleted strains (Ch2, AL, NC, and
Med-), as well as the 30-bp-deletion strains Ch1 and Med. Clones of the
carboxy terminus were prepared for each strain and used as positive controls for
the HTA to determine the migration position of each strain. Each sample was
analyzed with both an undeleted Ch2 and deleted Med probe at least twice
from independent PCRs. The probes were made as previously described (85).
The heteroduplex formation reaction was performed with 8 l of PCR product
of a strain control or patient sample, 1 l of annealing buffer (1 M NaCl, 100 mM
Tris-HCl [pH 7.5], 20 mM EDTA), and 1 l of 35S-radiolabeled probe. The
mixtures were denatured for 5 min at 100°C, allowed to reanneal for 4 min at 4°C,
separated on nondenaturing 10% polyacrylamide gels (Hoefer apparatus; Phar-
macia Biotech, San Francisco, Calif.), dried in a gel dryer (Bio-Rad, Hercules,
Calif.), and exposed to a PhosphorImager (Molecular Dynamics, Sunnyvale,
Calif.).
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HLA typing. The samples were HLA typed by using the micro-SSP HLA class
I DNA typing tray (One Lambda, Inc., Canoga Park, Calif.).
HLA epitope prediction. HLA epitopes were predicted for each consensus
LMP1 strain, as well as the full-length LMP1 sequence of the tumor biopsies, by
using the HLA Peptide Binding Prediction of BioInformatics and Molecular
Analysis Section available at (http://bimas.dcrt.nih.gov/molbio/htabind/).
Statistical methods. For data that was in the paired format, the statistical
method used was McNemar’s test of equality of paired proportions. For data
categorized into two by two contingency tables, the Fisher exact test was used to
detect differences between proportions. Statistical analyses were performed with
SAS statistical software (version 8.2; SAS Institute, Inc., Cary, N.C.).
Nucleotide sequence accession numbers. The complete LMP1 nucleotide se-
quences of the different strains are available under the following GenBank
accession numbers: AY337721, AY337722, AY337723, AY337724, AY337725,
and AY337726. The strains are reported with four of the 33-bp repeats, although
a range of two to six repeats was detected, with four or five being the most
common.
RESULTS
Analysis of the transmembrane domain sequence of LMP1.
Seven distinct strains of LMP1 that can be clearly distinguished
by characteristic base pair changes in the carboxy terminus
have previously been described (18). Strain changes in the
amino terminus of LMP1 also correlate but do not distinguish
the strains as clearly (18). In the present study the transmem-
brane domain of LMP1 comprising amino acids (aa) 25 to 187
was sequenced to determine whether distinguishing changes
between strains were present in the transmembrane domain.
Samples sequenced over the transmembrane domain of LMP1
include one B958 strain (sample N2 TW); three previously
described Med strain samples (NPCs C15 and C17 and HLP
11), as well as NPC 4 and Mono 80, 82, and 84; five previously
described Ch1 strain samples (NPCs 13, 23, 36a, 38, and 39), as
well as GX1-6T, -15T, -18T, and -19T and Mono 43, 72, 81, 85,
and 87; three previously described Ch2 strain samples (NPCs
19, 24, and 27); two previously described AL strain samples
(NPC 60 and pOT); and two previously described NC strain
sample (PTL1 and Mono 2) (18).
The consensus sequence of each strain was determined by
alignment with the Vector NTI computer program of the sam-
ples that grouped together on the phylogenetic tree drawn
from the alignment of the 35 samples. Many of the strains
share common coding and noncoding base pair changes in the
transmembrane domain (Fig. 1). The Med strain samples had
the least number of base pair changes compared to B958 in the
coding region of LMP1. The Ch1 strain shared changes with
the Med strain but also had additional changes. Unique base
FIG. 1. Sequence variation and corresponding amino acid changes in the computer-derived consensus sequence of the transmembrane domain
of the six strains of LMP1. Numbers across the top row correspond to the EBV genome coordinates; names in the left column refer to the six
identified LMP1 strains. The base pair and the amino acid changes are in boldface.
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pair changes in the Ch1 strain resulted in amino acid changes
150D3A and 178L3M, with silent changes at aa 93, 114, and
186. Base pair changes unique to the Ch2 strain were detected
at aa 33, 84, 91, 95, 124, and 144. A unique silent change was
found at aa 60. The AL strain samples also shared common
base pair changes with the Ch1 and Ch2 strains, but the
changes at aa 29, 63, 82, and 101 were unique to the AL strain
along with the silent change at aa 48. The NC strain had similar
base pair changes to the Ch1, Ch2, and AL strains; however,
this strain had numerous unique changes in the coding region
of the transmembrane domain of LMP1 that included the
changes at aa 26, 37, 43, 101, 109, 148, 155, and 179. Silent
changes were found at aa 56 and 100 (Fig. 1).
Phylogenetic analysis of the consensus transmembrane and
carboxy-terminal LMP1 amino acid sequences. Previous work
has shown that seven LMP1 strains can be distinguished by
distinct changes in the carboxy terminus (18). Since the trans-
membrane domain also showed common and distinct aa
changes among the LMP1 strains, it was of interest to deter-
mine whether the transmembrane domain also distinguished
EBV strains and, if so, whether there was a similar correlation
among the strains. Distant matrices were calculated from the
amino acid sequences of the transmembrane domain of the
samples, along with the computer-derived consensus for each
strain and phylogenetic trees, were inferred by using neighbor
joining (45, 80). The unrooted tree produced had six branches,
since the Med/ strains could not be distinguished since they
differ only in the presence or absence of the 30-bp deletion,
and all samples of a strain grouped with their consensus se-
quence (Fig. 2A). The B958 and Med strains were similar to
each other, as were the Ch2 and AL strains (Fig. 2A). The Ch1
strain divided into subgroups by the absence of a consensus
change or the presence of an additional change. Samples 15T
and GX6T are missing the change at aa 144; 18T, GX4T, NPC
36, and Mono 86 are missing the characteristic change at aa 46.
In contrast, Mono 43, 72, 85, 87, and 81 have an R3G muta-
tion at aa 132. The other Ch1 samples (GX3T; NPCs 13, 38, 39,
and 23; and 19T) contain sporadic but different changes (data
not shown).
The phylogenetic tree inferred from the distances matrices
calculated from the carboxy-terminal amino acid sequences of
the samples and the computer-derived consensus sequence for
each of the seven LMP1 strains revealed results similar to
those obtained from analysis with the transmembrane domain
(Fig. 2B). All samples again grouped with their consensus
sequence. The Ch1 strain again had two branches with the
lower branch representing samples with a sporadic change or a
D at 335, whereas many in the upper branch shared an L at aa
195 and a D at aa 335 (data not shown and Fig. 2B). The trees
derived from the LMP1 sequences further strengthen the clas-
sification of these patterns as true phylogenetically distinct
strains.
Full-length LMP1 sequence and mapping of known and
computer-predicted HLA-restricted epitopes. LMP1 and
LMP2 are among the few viral proteins expressed in latent
EBV infections in NPC and HD (7, 32, 72). Due to this re-
stricted protein expression, the LMP1 and LMP2 proteins re-
main the only clear candidates for CTL-based therapy. Several
functional epitopes have been described for LMP1, with the
majority restricted to HLA-A2, so use of computer prediction
FIG. 2. Identification of the LMP1 strains by phylogenetic analysis. (A) Phylogenetic tree drawn from amino acid sequences of the transmem-
brane domain of the computer-derived consensus sequences of the seven (the Med and Med strains are identical in the transmembrane domain)
previously identified LMP1 strains and the 35 samples. (B) Phylogenetic tree drawn from the consensus carboxy-terminal amino acid sequences
of the seven previously identified LMP1 strains and the 35 samples.
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models may allow for the identification of additional epitopes
presented by haplotypes found in NPCs (17, 43, 58, 70). Due to
the sequence variation in LMP1, the computer prediction
model can also predict possible epitope functionality differ-
ences between the strains of LMP1. The majority of the known
HLA-restricted epitopes scored in the top 10 of the epitopes
predicted for an HLA-restriction by computer, suggesting con-
gruency between the known and predicted epitopes. The ma-
jority of the computer-predicted epitopes discussed in this
analysis of strains were in the top six of the strong scorers of
the HLA restriction.
Previously identified restricted epitopes were identified
within these strains of LMP1 (Fig. 3). Several changes in amino
acid sequences of the known epitopes were detected in the
different strains, including three of the known A2-restricted
epitopes at positions 51, 92, and 125 (Fig. 3) (17, 43). All of the
strains except B958 have changes in the A2-restricted epitope
at 125 (YLL) (Fig. 3). The Ch2 and AL strains have changes in
the epitope at position 51 (ALL) and Ch2 also has a change in
the epitope at 92 (LLL) (Fig. 3). The Ch1, Ch2, AL, and NC
strains have changes in the B40/B61/B27-restricted epitope at
position 72 (FRR), and the AL and NC strains have changes in
the B51-restricted epitope at position 375 (DPH) (Fig. 3) (58,
70).
Several other functionally identified epitopes of unknown
HLA restriction also differed among the LMP1 strains, includ-
ing the epitopes at positions 38 (FWL), 52 (LLV), 183 (WMY),
185 (YYH), 189 (QRH), 310 (PSD), and 314 (AGN) (Fig. 3)
(17, 58). To determine whether these and other possible
epitopes differed between the LMP1 strains, the LMP1 con-
sensus sequence of each strain was analyzed for HLA-re-
stricted epitopes by using a computer based prediction model.
Numerous predicted HLA-restricted epitopes scored markedly
different among the LMP1 strains. The most notable was the
A2-restricted epitope at position 125 (YLL) that had the high-
est output score by the computer, indicating a possible strong
reaction in vivo. This epitope has been previously identified to
be a functional epitope (43). This A2-restricted epitope was
only present in the B958 and Med strains and when actual
strain variants of this epitope have been tested, a much re-
duced response has been observed supporting the use of the
computer prediction model (17). The HLA-B14 and -B27 pre-
dicted epitope at position 13 (RRP) also scored only or much
higher in the B958 and Med strains than the Ch1, Ch2, AL, and
NC strains. These predicted differences in reactivity may con-
tribute to evasion of the immune response.
HTA analysis of NPC and matching blood from areas of
endemicity and nonendemicity. The HTA based on strain-
defining changes in the carboxy terminus of LMP1 has proved
to be a powerful tool in determining the LMP1 strains of EBV
in a sample (84, 85). The seven strains migrate uniquely when
screened with both a deleted (Med) and undeleted (Ch2)
probe (Fig. 4) (85). In previous studies, compartmental differ-
ences in strain prevalence were detected between the oral
cavity and PBL in asymptomatic carriers and infectious mono-
nucleosis patients (83, 84).
To determine whether strains differed between tumor and
matching PBL, samples were screened by using the LMP1
HTA. Ten NPCs from the southern region of China were
analyzed by HTA where NPC is endemic. Nine of the ten
NPCs (GX1, GX2, GX3, GX4, GX5, GX6, 138, 139, and 141)
had the Ch1 strain present in the tumor, as shown by the
migration on the HTA with both the Med and Ch2 probes
(Fig. 4A). It has been previously shown that strains that con-
tain additional sequence changes from the known controls
have a slightly altered migration (Fig. 4A). Thus, the Ch1 band
in tumor sample GX3 ran higher with the Med probe due to
two additional base pair changes at positions 168239 and
168300 and the Ch1 band in GX6 due to changes at positions
168246 and 168300 (Fig. 4A). The final endemic sample, NPC
140, had the Ch2 strain (Fig. 4A). The identification of specific
strains by HTA was confirmed by using the Ch2 probe (Fig.
4A). These data revealed that a single strain was usually de-
tected in the tumors.
The strain profile of the matching PBL was quite different
than the tumor. Interestingly, the matching PBL from the
region where NPC is endemic had predominantly or only the
B958 strain (Fig. 4A). In PBL samples from GX1, GX2, GX4,
GX5, and GX6, the predominant strain detected was B958
(Fig. 4A). GX3 PBL had both the B958 and Med strain (Fig.
4A). The Ch1 strain was prevalent in the PBL and tumor of
sample 138 (Fig. 4A). Sample 139 contained the Ch1 strain in
both the tumor and PBL (Fig. 4A). In sample 141, the Ch1
strain was detected in the tumor and Med in the PBL (Fig.
4A). Sample 140 had the Ch2 strain in the tumor and the
Med and Ch1 strains in the PBL (Fig. 4A). In most cases (9
of 10) the LMP1 variants detected in the tumor were also
faintly detected in the PBL after long exposure of the film
(data not shown). Using the McNemar’s test for equality with
the paired endemic samples, we found it statistically significant
that the Ch1 strain was consistently in the tumor but not the
predominant strain in the PBL (P  0.0156). Combining all of
the HTA data from the samples in the present study and other
samples analyzed in the lab for a total of 26 endemic tumor
samples and 11 endemic PBL samples, the sample size was
sufficient to be able to detect an association between the pres-
ence (or absence) of a particular strain in either the endemic
tumors or the endemic PBL by using the Fisher exact test (data
not shown). It was highly statistically significant that the B958
strain that was consistently detected in the blood (7 of 11
samples) was never detected in the tumors of the endemic
NPCs (0 of 26 samples) (P  0.0001), and the Med strain
present in blood (4 of 11 samples) was not detected in the
endemic tumors (0 of 26 samples) (P  0.005) (Table 1). These
compartmental differences suggest a possible selection against
these strains in NPC.
Eight NPCs from the northern region of China where NPC
was not endemic, six with matching blood, were screened by
HTA. Six of the nonendemic NPC samples contained the Ch1
strain (i.e., samples 15, 17, 18, 108, 509, and 19) (Fig. 4B). NPC
614 contained the Ch2 strain, and NPC 22 contained the Med
strain with two additional base pair changes at positions
168246 and 168348 (Fig. 4B and data not shown). Although
sample 15 had Ch1 in the tumor, the PBL had Ch2, Med, and
Med strains (Fig. 4B). NPCs 17 and 18 had multiple strains in
the blood, including Ch2, NC, B958, Med, Med, and Ch1
(Fig. 4B). The tumor of subject 108 revealed the Ch1 strain
(with additional changes), whereas the PBL contained pre-
dominantly Med (Fig. 4B). Sample 509 had strains B958,
Med, and Ch1 in the PBL and Ch1 in the tumor (Fig. 4B).
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FIG. 3. Full-length consensus amino acid sequence of the LMP1 strains with previously described and computer-predicted HLA epitopes. The
amino terminus is depicted in black; the transmembrane domain is depicted in green; and the carboxy terminus is depicted in blue. Amino acid
changes from B958 consensus are shown in red, and deletions are shown with a forward slash (/). Vertical lines separate the exons. Previously
described functional HLA epitopes are shown in black with the HLA restriction; a “?” refers to functional epitopes of unknown restriction.
Computer-predicted epitopes that score differentially among the strains are shown in red.
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Sample 614 had Ch1 and Med strains in the PBL, with the
Ch2 strain in the tumor (Fig. 4B). With long exposure, sample
19 was found to have the Ch1 strain in the PBL and, in most
cases (6 of 7 samples), the strain detected in the other nonen-
demic NPCs was faintly detected in the PBL (data not shown).
All strains detected with the Ch2 probe were confirmed with
the Med probe (data not shown). Although the Ch1 strain
was prevalent in the NPCs from both regions of endemicity and
nonendemicity, the B958 strain was prevalent in the PBL of
patients from areas where NPC was endemic, and multiple
LMP1 strains were detected in patients from areas where NPC
was not endemic (Fig. 4). Importantly, the strain in the tumor
was usually not the prevalent strain in the blood in the majority
of cases (12 of 16 samples). Combining all HTA data from the
samples in the present study and others analyzed in the lab for
a total of 26 nonendemic tumors and 7 nonendemic PBL sam-
ples, a Fisher exact test to determine associations between the
presence or absence of a particular strain in nonendemic tu-
FIG. 4. (A) Strain profile of EBV in NPC and matching blood of patients from the region of China where NPC is endemic, as determined by
LMP1 HTA with Med and Ch2 probes. The first seven lanes correspond to control lanes for migration of the different strains. NPC tumor (lanes
T) and peripheral blood (lanes B) strains were identified based on their migration in relation to the controls. (B) Strain profile of EBV in NPC
and matching blood of patients from the region of China where NPC is not endemic, as determined by LMP1 HTA with Ch2 probe. The first three
lanes correspond to control lanes for the migration of the different strains. NPC tumor (lanes T) and peripheral blood (lanes B) strains were
identified based on their migration in relation to the controls.
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mor or PBL indicated that it was statistically significant that (i)
the Med strain, which was detected in six of seven PBL
samples, was present in only 3 of 26 tumors (P  0.0005); (ii)
the NC strain, which was detected in four of seven PBL sam-
ples, was not present in the tumors (0 of 26) (P  0.0009); (iii)
the Med strain detected in three of seven PBL samples was
not detected in the nonendemic tumors (0 of 26) (P  0.006);
and (iv) the B958 strain present in three of seven PBL samples
was not detected in the tumors (0 of 26) (P  0.006) (Table 1
and data not shown). The striking absence of certain LMP1
strains in the tumors again suggests a possible selection against
these strains in NPC.
HLA typing and epitope sequencing of samples from areas
of endemicity and nonendemicity. Specific HLA haplotypes,
notably A2 and B46, have been shown to be prevalent in NPC
patients (35, 50). The data presented here indicate that in the
Ch1 strain several A2-restricted epitopes are altered, suggest-
ing that changes in HLA-restricted epitopes in LMP1 variants
may result in reduced immune recognition. Since there was a
striking difference in the LMP1 strain detected in the tumors
compared to the PBL, several of the samples from areas of
endemicity and nonendemicity were HLA typed (Table 2). The
majority of samples were HLA-A24 or -A2 restricted.
To determine whether possible changes were present in
HLA-restricted epitopes and to confirm that the strain identi-
fied by HTA of the carboxy terminus was consistent through-
out the gene, the full-length sequence of LMP1 of these tumor
samples was determined, and HLA-restricted epitopes were
predicted for each protein sequence by computer analysis. All
10 tumor samples were found to have the characteristic strain
changes throughout the full-length LMP1, as predicted by the
HTA strain, although some had minor base pair change dif-
ferences (data not shown). For example, GX1T was predicted
by HTA to contain the Ch1 strain in the carboxy terminus, and
analysis of the amino terminus and transmembrane domains
confirmed the corresponding characteristic Ch1 base pair
changes in these regions.
When the scores of the computer-predicted epitopes from
the full-length LMP1 sequences of the tumors were compared
to B958 sequence, which was not present in the tumors,
marked differences could be found. Although changes were
not found in the known A2-restricted epitopes ALLVLYSA
(ALL), LLLIALWNL (LLL), and YLQQNWWTL (YLQ),
the known epitope YLLEMLWRL (YLL) was predicted not to
be recognized in the Ch1, Ch2, AL, and NC strains (Table 3)
(43). This epitope scores the highest of all LMP1 epitopes
predicted by the computer, and functional studies have shown
that the Ch1 changes in this epitope render it less responsive in
vitro (17, 40). Four of the A2-restricted tumors (GX6, -15, -18,
and -19) had the characteristic Ch1 changes at positions 126
and 129, and one tumor (GX3) had a different change at
position 126 (Table 3). Most interestingly, the A2-restricted
22T that had the Med strain by HTA and full-length sequenc-
ing had an additional nonconsensus change at position 130 that
rendered this epitope less responsive by computer prediction
(Table 3). All five Ch1 strain samples (GX3T, GX6T, 15T,
18T, and 19T) were predicted by computer to not react to the
predicted A2 epitope at position 118, LVL, due to amino acid
changes at positions 122 and 126 (Table 3). These changes in
the A2 epitopes at positions 118 and 125 were changed in the
2 or 9 position, known to be critical for binding to MHC-I (71).
NPC 19T had additional mutations in aa 172, 173, and 154 that
rendered the known A2 epitope at position 167, LLV, nonre-
active and the predicted epitope at position 152, ILL, fourfold
less reactive than B958 (Table 3) (43).
Since functional A24-restricted epitopes have not been iden-
tified and many of the NPC samples were A24 restricted, the
computer-predicted epitopes were identified. Four HLA-A24-
restricted epitopes identified in the B958 sequence were pre-
dicted to be nonfunctional in the Ch1 sequence. All six of the
A24-restricted samples had changes in all four epitopes. GX1,
GX2, GX3, GX4, and GX5 had three changes in the A24-
restricted 143 epitope, FFL, due to the characteristic Ch1
strain changes in LMP1 found in the tumor, and one sample
(GX6) had two of the changes but lacked the characteristic
Ch1 change at aa 144 (Table 3). All six A24 typed samples
(GX1 to -6) had two changes in the predicted epitope at
position 17, RGP, three changes in the predicted epitope at
330, KGG, as well as two changes in the predicted epitope at
118, LVL, due to the characteristic Ch1 strain changes in the
tumors (Table 3).
The HLA-A33-restricted sample 22 also responded two fold
less to the A33 computer-predicted epitope at position 65, IIL.
This change in sample 22T at aa 66 is not a consensus Med-














T PBL T PBL
B958 0/26 7/11 0.0001 0/26 3/7 0.006
Med 0/26 4/11 0.005 3/26 6/7 0.0005
Med 0/26 1/11 0.3 0/26 3/7 0.006
Ch1 21/26 8/11 0.67 17/26 7/7 0.15
Ch2 5/26 1/11 0.65 6/26 3/7 0.36
NC 0/26 1/11 0.3 0/26 4/7 0.0009
AL 0/26 0/11 0/26 0/7
a P values were calculated by using the Fisher exact test, analyzing for the
presence of strain versus location (i.e., tumor [T] or PBL).




LMP1 strain HLA-A HLA-B
Tumor PBL 1 2 1 2
Endemic
GX1 Ch1 B958 A24 B35 B15
GX2 Ch1 B958 A24 B13 B51
GX3 Ch1 B958 A2 A24 B40 B40
GX4 Ch1 B958 A11 A24 B27 B40
GX5 Ch1 B958 A24 A33 B51 B58
GX6 Ch1 B958 A2 A24 B46
Nonendemic
15 Ch1 Multiple A2 A11 B13 B46
18 Ch1 Multiple A2 B51
19 Ch1 Ch1 A1 A2 B7 B15
22 Med NDa A2 A33 B44 B15
a ND, not determined.
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sequence change (Table 3). The HLA-B35-restricted epitope
predicted at position 81, GAL, did not score with the charac-
teristic Ch1 strain changes at aa 82, 84, and 85 found in GX1T
(Table 3).
Changes were not detected in the Ch1 strain in the known
B51-restricted epitope at position 375, DPH, possibly since this
epitope encompasses the PxQxS motif that is important for
signaling (Fig. 3) (58, 70). However, the three HLA-B51-typed
samples (GX2, GX5, and 18) had a much weaker predicted
response to the B51 predicted epitopes at position 114, FGC,
and at position 81, GAL, due to the characteristic Ch1 changes
at positions 122, 82, 84, and 85 (4- and 12-fold, respectively)
(Table 3).
Similarly, the B40 typed samples (GX3 and GX4) were pre-
dicted not to react to the known epitope at 74, RDL, and the
predicted epitope at position 45, SDW, due to the character-
istic Ch1 changes at aa 82 and 46 and displayed a much weaker
response to the predicted epitope at 149, LDL, due to the
amino acid changes at positions 150 and 151 (Table 3) (58, 70).
Possible anchoring amino acids in the epitopes were again
changed.
Although the HLA-B27-typed GX4 did not have changes in
the known B27 epitope at position 72, FRR, the computer-
derived epitope at position 13, RRP, was predicted to be 30-
fold less reactive due to characteristic Ch1 amino acid changes
at positions 13 and 17 (58, 70). Similarly, the epitope predicted
at aa 189, QRH, in the B95 strain was not identified due to Ch1
changes at aa 189 and 192 in the tumor (Table 3) (58). The
QRH epitope has been previously described, but the HLA
restriction is unknown, although it is thought not to be HLA-
B27 restricted (17).
GX5, HLA-B58 typed, did not have changes in the known
epitope at position 156, IAL, but due to two additional changes
from the Ch1 strain LMP1 sequence at aa 221 and 225 had a
weaker predicted response to a predicted epitope at position
218, NSN (Fig. 3 and Table 3) (17). The NSN epitope has been
described as a functional epitope, but the restriction is un-
known (17).
These data indicate that the strains detected in NPC had
changes in several of the potential epitopes of LMP1 presented
by a specific HLA of the patient. The prevalence of specific
strains in tumors with changes in these epitopes may contribute
to reduced immune recognition of virus-infected cells. Com-
puter predictions for the other HLA haplotypes identified in
these samples (B13, B15, and B46) are not available.
LMP2 sequence of known HLA-restricted epitopes. LMP2 is
expressed in NPC tumors and also in latently infected periph-
eral blood memory B cells and has been shown to induce a
TABLE 3. Known and predicted HLA-restricted epitopes in LMP1 and the variants found in NPC that showed a marked decrease in
reactivity as determined by computer compared to B958-like epitopes
HLA Positiona B958-like epitope [sample(s)]b Variant epitope(s) in Ch1 and Med strains [sample(s)]b
A2 51* ALLVLYSFA (GX3T, GX6T, 15T, 18T, 19T, 22T)
92* LLLIALWNL (GX3T,GX6T,15T,18T,19T, 22T)
125* YLLEMLWRL YFLEILWRL (GX6T, 15T, 18T, 19T), YILEILWRL (GX3T),
YFLEIFWRL (22T)
159* YLQQNWWTL (GX3T, GX6T, 15T, 18T, 19T, 22T)
167* LLVDLLWLL (GX3T, GX6T, 15T, 18T, 22T) LLVDLVRLL (19T)
118 LVLGIWIYL (22T) LVLGLWIYF (GX6T, 15T, 18T, 19T), LVLGLWIYI (GX3T)
152 ILLIIALYL (GX3T, GX6T, 15T, 18T, 22T) ILVIIALYL (19T)
A24 143 FFLAFFLDL FILAFFLAI (GX1T, GX2T, GX3T, GX4T, GX5T),
FFLAFFLAI (GX6T)
17 RGPPLSSSL LGPPLSSSI (GX1T, GX2T, GX3T, GX4T, GX5T, GX6T)
330 KGGDQGPPL KGGRDGPPS (GX1T, GX2T, GX3T, GX4T, GX5T, GX6T)
118 LVLGIWIYL LVLGLWIYF (GX2T, GX4T, GX5T, GX6T), LVLGLWIYI
(GX1T, GX3T)
A33 65 IILIIFIFR (GX5T) ILLIIFIFR (22T)
B35 81 GALCILLLM GGLGLLLLM (GX1T)
B51 375* DPHGPVQLSYYD (GX2T, GX5T, 18T)
114 FGCLLVLGI FGCLLVLGL (GX2T, GX5T, 18T)
81 GALCILLLM GGLGLLLLM (GX2T, GX5T, 18T)
B40 74* RDLLCPLGA RDLLCPLGG (GX3T, GX4T)
45 SDWTGGALL SNWTGGALL (GX3T, GX4T)
149 LDLILLIIA LAIILLIIA (GX3T, GX4T)
B27 72* FRRDLLCPL (GX4T)
13 RRPPRGPPL PRPPLGPPL (GX4T)
189 QRHSDEHHH PRHTDELHH (GX4T)
B58 156* IALYLQQNW (GX5T)
218 NSNEGRHHL NSNDGRHLL (GX5T)
a The position corresponds to the B958 amino acid sequence of LMP1. Known LMP1 epitopes are indicated by an asterisk.
b T, tumor. Mutations in the epitopes are indicated in boldface.
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stronger CTL response than LMP1 (77). Consequently, LMP2
sequence was determined from the two compartments to eval-
uate possible epitope changes that could also contribute to the
difference in the prevalence of one strain in the tumor versus
the strains detected in the blood. LMP2 sequences from the
tumor samples of nine patients (GX1, GX2, GX3, GX4, GX5,
GX6, 18, 19, and 22) and the blood samples from four patients
(GX1, GX2, GX5, and 19) were determined. Variation was
detected in LMP2 from the Chinese samples, but in most cases
the same changes were found in the tumor and blood. Of the
six known HLA-A2-restricted epitopes, a change was only
identified in the known A2 epitope at position 426, CLG. This
epitope was changed in GX6T, 18T, 19B, and 22T but not in
GX3T or 19T (Table 4) (52). This change in this epitope has
been shown not to affect reactivity, and the computer also
predicted no change in reactivity (52). The remaining tumor
samples did not have changes in the known A2 epitopes, sug-
gesting that the tumors and PBL would be equally recognized
by LMP2-specific CTL (Table 4) (49).
Of the six A24-restricted patients (GX1, GX2, GX3, GX4,
GX5, and GX6), tumor and blood samples were unchanged in
the known epitope at aa 222, whereas all had changes in the
known A24 epitope at position 419, TYG (Table 4) (58). How-
ever, this change was also found in the PBL from GX1, GX2,
and GX5. Similarly, the computer-predicted A24-restricted
epitope at 170 (SYAAAQRKL) was changed in all of the A24
samples (SSA), but this change was also found in the matched
PBL samples.
The known A11-restricted epitope at position 341, SCS, was
unchanged in GX4T; however, the known B27 epitope at po-
sition 236, RRR, had a change and by computer was predicted
to be threefold less reactive (58). The known B40-restricted
epitope at position 200, IED, was changed in GX3T and, as
determined by computer prediction, is fivefold less reactive.
Again, possible anchoring positions of the epitope were
changed (Table 4) (49, 58).
However, several of the described epitopes of unknown re-
striction were changed in some samples (Table 4) (58). The
epitope at position 61, EDP, had two changes in two of the
samples (19T and 22T) from regions where NPC is not en-
demic and one change in a sample (GX5T) from a region
where NPC is endemic, but it was unchanged in samples
GX2T, GX3T, GX4T, and GX6T from areas of endemicity
(Table 4) (58). GX4T had three changes in the epitope at
position 121, NPV; however, six of the tumor samples did not
have changes (Table 4) (58). The epitope at position 141, ASC,
was unchanged in 19T, whereas the tumor samples from GX2,
GX3, GX5, 18, and 22 had one amino acid change (Table 4)
(58). Sample 19T did not have a change in the known epitope
at position 249, MFL, but two changes were detected in GX1T
and PBL, GX2T and PBL, GX4T, GX5T and PBL, GX6T,
18T, 19PBL, and 22T (Table 4) (58). This described epitope
overlaps a predicted A2 epitope (IMFLACVLV) that is pre-
dicted to be much less reactive with the amino acid changes
(MMMFLACLVV) seen in the samples. Only sample 19,
which had the same Ch1 LMP1 strain in the tumor and PBL,
had a different LMP2 sequence in the tumor compared to the
blood, with the blood LMP2 being more variant. The changes
TABLE 4. Sequence of known and predicted LMP2 epitopes from NPC and PBL from regions of endemicity and nonendemicity
HLA Positiona Consensus (B958) epitope [sample(s)]b Variant epitopes [sample(s)]b
A2 292* GGLGTLGAAL (GX6T, 18T, 19T and -B, 22T)
329* LLWTLVVLL (19T)
356* FLYALALLLLAS (GX3T, GX6T, 18T, 19T and -B, 22T)
426* CLGGLLTMVA (GX3T, 19T) SLGGLLTMVA (GX6T, 18T, 19B, 22T)
447* LLSAWILTAGF (GX3T, GX6T, 18T, 19T and -B, 22T)
453* LTAGFLIFLI (GX3T, GX6T, 18T, 19T, and -B, 22T)
A24 222* IYVLVMLVL (GX1T and -B, GX2T and -B, GX3T, GX4T,
GX5T and -B, GX6T)
419* TYGPVFMCL TYGPVFMSL (GX1T and -B, GX2T and -B,
GX3T, GX4T, GX5T and -B, GX6T)
170 SYAAAQRKL SSAAAQRKL (GX1T and -B, GX2T and -B,
GX3T, GX4T, GX5T and -B, GX6T)
A11 341* SCSSCPLSK (GX4T)
B27 236* RRRWRRLTV LRRWRRLTV (GX4T)
B40 200* IEDPPFNSLLF IEDPPFNSILF (GX3T)
?c 61 EDPYWGNGDRHSDYQ (GX2T, GX3T, GX4T, GX6T) EDLDWGNGDRHSDYQ (19T, 22T),
EDLYWGNGDRHSDYQ (GX5T)
121 NPVCLPVIVAPYLF (GX2T, GX3T, GX5T, 18T, 19T, 22T) LPLCLRVIVAPYLF (GX4T)
141 ASCFTASVSTVVTAT (19T) ASCFTASVSTVVSAT (GX2T, GX3T,
GX5T, 18T, 22T)
249 MFLACVLVLIVDAV (19T) MFLACLVVLIVDAV (GX1T and -B, GX2T
and -B, GX4T, GX5T and -B, GX6T 18T,
19B, 22T)
a The position corresponds to B958 amino acid sequence of LMP2. Known LMP2 epitopes are indicated by an asterisk.
b T, tumor; B, PBL. Mutations in the epitopes are indicated in boldface.
c ?, epitope(s) of unknown HLA restriction.
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that were found in these potential epitopes of LMP2 may
render the virus less susceptible to immune surveillance; how-
ever, in all but one example the LMP2 was the same in the
blood and tumor and would be equally recognized by the
immune system. The fact that a common LMP2 strain was
found in the Chinese population regardless of the LMP1 strain
suggests that immune recognition of LMP2 likely does not
account for the difference in strain prevalence between the
blood and tumor samples.
DISCUSSION
The data presented here further reveals that the seven phy-
logenetically distinct strains of LMP1 previously identified by
amino acid changes in the carboxy terminus are also distin-
guished by amino acid changes throughout the protein (18).
Interestingly, identification of LMP1 variants by using HTA
indicates that there are striking differences in relative abun-
dance of the variants between the samples of NPCs and PBL.
The frequent detection of the Ch1 strain in NPC has been
suggested to reflect the high prevalence of Ch1 in the general
population. However, the data presented here reveal that the
B958 strain is also prevalent in peripheral blood samples from
the region of China where NPC is endemic, although the B958
strain is rarely found in NPC. In the majority of samples from
this region, a single different strain was detected in the NPC
and PBL samples, whereas multiple LMP1 variants were de-
tected in the PBL samples from the region of China where
NPC is not endemic. The absence of some of these variants
within the tumor is highly statistically significant and suggests a
selection against their presence within the tumors. Impor-
tantly, the strains detected in all examples of tumors with a
given HLA restriction had changes in several of the known and
predicted HLA epitopes within LMP1 in comparison with the
strains detected in the PBL that retained the epitope sequence.
It is possible that the changes that are characteristic of the Ch1
strain in several HLA-restricted epitopes may result in de-
creased binding and presentation by MHC-I and/or less-effi-
cient recognition by the T-cell receptor.
The HLA-A11 haplotype is a dominant allele in China;
however, the present study and previous studies have deter-
mined that most NPC patients are HLA-A2 or -A24 restricted
(35, 50, 53). Although A2 and A24 alleles are prevalent in the
general population of China, they are found more frequently in
NPC patients, which suggests a possible relationship between
HLA type and the development of NPC (12). The majority of
the identified epitopes in LMP1 and LMP2 are restricted
through HLA-A2 (58). Since A24-restricted epitopes have not
been identified in LMP1 and since the majority of the NPC
samples analyzed were A24 restricted, computer prediction
enabled additional analysis. The data presented here reveal
that many of the A2- and A24-restricted LMP1 epitopes are
changed in the Ch1 and Ch2 strains that were predominant in
the tumors in comparison with some of the strains found in the
PBL of the same patient. Many of these changes were in
anchoring positions within the epitopes and could possibly
interfere with MHC-I binding (71). An example is the known
A2-restricted YLL epitope, which has been shown to induce a
much weaker CTL response in a chromium release assay when
the amino acid changes characteristic of Ch1 were tested (17,
40).
Although many of the known and predicted A2-restricted
epitopes had potentially significant changes, not all of the A2
epitopes are altered in the Ch1 strain, and the functional
epitopes at aa 51, 92, and 156 should be presented in A2-
restricted individuals with the Ch1 strain. Intriguingly, several
studies to identify LMP1 epitopes have shown that in Asian
populations A2-restricted healthy individuals respond with
much less frequency than A2-restricted healthy Caucasians to
the identified epitopes at 51 and 159 spanning LMP1 (17, 50).
It has been shown that multiple epitopes of a common HLA
restriction may exist within a single protein and, within the
EBNA3B protein, multiple A11 epitopes have been identified
(25). A screen of individual responses revealed that most in-
dividuals responded to one strong epitope but that the degree
of response to other epitopes was variable in presence and
strength (25). Considering the multiple known and predicted
A2 epitopes in LMP1, it is possible that in Asian populations
the presentation of the epitopes at 51, 92, or 159 is apparently
nonexistent or undetectable. Thus, the Ch1 consensus se-
quence changes within the strong epitope at 125 could elimi-
nate presentation of LMP1 in Asian A2-restricted individuals.
LMP1 is not expressed in latently infected PBL but is de-
tected in a considerable proportion of NPC and HD tumors
and is thought to be expressed in all cells in early, preinvasive
examples of NPC (73). Malignant cells that express LMP1 but
are not recognized due to epitope changes in LMP1 would
persist, and cells whose LMP1 epitopes are recognized would
be eliminated. This negative selection of the immune system
on strains detected in the blood would be reflected in the
striking predominance of the Ch1 strain in the tumors.
It is of interest that many of the LMP1 variants had changes
in predicted HLA epitopes of various restrictions. This varia-
tion in potential immune recognition could contribute to the
development of EBV-associated diseases in distinct popula-
tions and individuals. Changes in HLA epitopes in the EBNA
proteins have also been identified within isolated populations
and likely contribute to the prevalence and persistence of spe-
cific EBV strains in populations (14). The strongest CTL re-
sponse to EBV has been shown to be directed against
EBNA3A, -B, and -C (40, 77). Interestingly, an escape mutant
of EBV in a posttransplant patient treated with CTL therapy
developed into a lethal lymphoma due to a deletion in
EBNA3B that encompassed two immunodominant CTL
epitopes (27). The sporadic, nonconsensus mutation in the
Med strain in the 22T sample, an A2-restricted sample, sug-
gests that sporadic mutations may also occur in LMP1 that
could enable immune escape.
In contrast to LMP1, the LMP2 sequences did not distin-
guish the strains in the tumor and PBL. Several A2- and A24-
restricted epitopes have been described for LMP2, and most
were unchanged in the tumors and PBL in the present study
(58). Many of these LMP2 epitopes, including the A2-re-
stricted FLY, CLG, and LLW and the A24-restricted TYG and
IYV, are presented in a TAP-independent manner (41, 47, 48).
The hydrophobic A2-restricted epitopes, LLS and CTA, may
also be presented in a TAP-independent manner and did not
have changes. It has been proposed that upregulation of TAP1
and TAP2 by LMP1 may lead to more efficient presentation of
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TAP-dependent epitopes, so TAP-independent epitopes (like
LMP2) may evade recognition by being diluted on the surface
of the cell (69). The decreased presentation of LMP2 on the
cell surface would decrease the selective pressure for epitope
changes, as well as enable the persistence of both tumor cells
and PBL expressing LMP2 (7, 10, 89). However, several pre-
dicted epitopes of LMP2 were changed and may contribute to
possible immune evasion in the peripheral blood and tumor.
Although multiple potential CTL epitopes are changed
among the variant LMP1, several strains have some changes in
common with the Ch1 and Ch2 strains and yet are not detected
in the tumors. This may indicate that differences in the biologic
properties of LMP1 variants are also a factor in the develop-
ment of cancer. LMP1 is a transmembrane protein that func-
tions as a constitutively activated member of the tumor necro-
sis factor receptor family (62). The protein contains three
distinct domains. The short 24-aa cytoplasmic amino terminus
anchors the protein in the membrane and regulates the turn-
over of the protein by ubiquitin-proteasome degradation path-
way (1, 91). The six transmembrane domains induce aggrega-
tion of LMP1 in the membrane (24). The carboxy terminus has
two activation domains, carboxy-terminal activating region 1
(CTAR1) and CTAR2, responsible for activation of NF-B,
JAK/STAT, and JNK (20, 26). All LMP1 strains retain the
PxQxT motif in CTAR1 and the PxQxS motif in CTAR2,
suggesting that all strains can interact equally with the TNF
receptor associated factors leading to NF-B activation (6, 15,
19, 37, 38, 81). One notable change among the strains of LMP1
is at aa 129, where only the B958 strain retains the methionine
for the lytic LMP1; consequently, only the B958 strain can
produce lyLMP1. Lytic LMP1 has been suggested to negatively
regulate LMP1 activation of NF-B (21). Increased AP1 and
NF-B activation has been reported with the Ch1 and NC
strains (using our nomenclature), and increased activation of
NF-B and upregulation of epidermal growth factor receptor
has been observed with the Med strain in comparison with
B958 (22, 60). These differences in signaling map to the amino
terminus and the transmembrane domains of LMP1 (5, 39, 60).
There are potential sequence differences in the amino and
transmembrane domains that may be responsible. Decreased
NF-B and AP1 activation have been described for a substrain
of Ch1 that lacks the first four amino acid changes in the amino
terminus characteristic of Ch1 (aa 3, 13, 17, and 25) (22). This
Ch1 substrain has been detected in several NPCs and is the
prevalent Ch1 strain in European and American asymptomatic
carriers and infectious mononucleosis subjects (data not
shown) (18). These same changes in the four amino-terminal
amino acids are also found in the Ch2 strain and may also
contribute to functional differences (18, 87). The Ch1 strain
found in the endemic NPCs was also found to frequently carry
a change at aa 335 (G3D), an amino acid change previously
shown prevalent in NPCs, but not in healthy Chinese subjects
(data not shown) (90). Secretion of LMP1 has been suggested
to have direct immunosuppressive effects on tumor-infiltrating
lymphocytes (16, 23, 56). This immunosuppressive ability maps
to aa 34 to 40 of LMP1, a region where only the NC strain has
a change (16). Perhaps the absence of the NC strain in NPC
reflects an inability of the NC LMP1 to inhibit T-cell prolifer-
ation and natural killer cytotoxicity. These potential differ-
ences in signaling and biologic properties of the LMP1 variants
may also contribute to differences in pathogenicity.
Multiple studies have suggested that the immune recogni-
tion of EBV-infected cells may be affected through several
mechanisms. In latently infected PBL, EBV expression is re-
stricted to EBNA1 and LMP2 (89). EBNA1 is not thought to
be presented by MHC-I and the TAP-independent epitopes
within LMP2 may not be efficiently presented (4, 55, 69). La-
tently infected lymphocytes that shift into a latent, proliferat-
ing mode of infection are eliminated due to CTL recognition
of the EBNA2 and EBNA3 proteins (77). Interestingly,
epitope changes have been identified in these proteins that
may facilitate persistence in populations with predominant
HLA types (8, 14). During the development of NPC, LMP1 is
expressed in the absence of the EBNAs, the major viral CTL
targets. The data presented here suggest the strain-specific
changes in HLA epitopes in LMP1 may enable its expression in
the tumors without recognition by LMP1-specific CTL. In sum-
mary, the striking consistent sequence variation of LMP1
strains may contribute to the transformation of epithelial cells
in NPC through reduced immune recognition and also through
differences in molecular and biologic properties that are yet to
be elucidated.
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